119 related articles for article (PubMed ID: 36729669)
1. Safety and Efficacy of Alendronate to Treat Osteopenia in Children During Therapy for Acute Lymphoblastic Leukemia: A Retrospective Cohort Study of Sequential Outcomes.
MacDonald P; Cranston A; Virdee M; Farncombe T; Athale U; Barr RD
J Pediatr Hematol Oncol; 2023 May; 45(4):200-206. PubMed ID: 36729669
[TBL] [Abstract][Full Text] [Related]
2. Alendronate for steroid-induced osteopenia in children with acute lymphoblastic leukaemia or non-Hodgkin's lymphoma: results of a pilot study.
Wiernikowski JT; Barr RD; Webber C; Guo CY; Wright M; Atkinson SA
J Oncol Pharm Pract; 2005 Jun; 11(2):51-6. PubMed ID: 16460605
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate therapy for reduced bone mineral density during treatment of acute lymphoblastic leukemia in childhood and adolescence: a report of preliminary experience.
Lethaby C; Wiernikowski J; Sala A; Naronha M; Webber C; Barr RD
J Pediatr Hematol Oncol; 2007 Sep; 29(9):613-6. PubMed ID: 17805035
[TBL] [Abstract][Full Text] [Related]
4. Bone mineral density in survivors of childhood acute lymphoblastic leukemia.
Athanassiadou F; Tragiannidis A; Rousso I; Katsos G; Sidi V; Papageorgiou T; Papastergiou C; Tsituridis I; Koliouskas D
Turk J Pediatr; 2006; 48(2):101-4. PubMed ID: 16848106
[TBL] [Abstract][Full Text] [Related]
5. Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.
Iwamoto J; Uzawa M
Clin Rheumatol; 2016 Jan; 35(1):205-12. PubMed ID: 25367347
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of bone metabolism in children with acute lymphoblastic leukemia after induction chemotherapy treatment.
Athanassiadou F; Tragiannidis A; Rousso I; Katsos G; Sidi V; Koliouskas D; Papastergiou C; Tsituridis I
Pediatr Hematol Oncol; 2005 Jun; 22(4):285-9. PubMed ID: 16020115
[TBL] [Abstract][Full Text] [Related]
7. Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age.
Jacobson DL; Lindsey JC; Gordon C; Hazra R; Spiegel H; Ferreira F; Amaral FR; Pagano-Therrien J; Gaur A; George K; Benson J; Siberry GK
Clin Infect Dis; 2020 Aug; 71(5):1281-1288. PubMed ID: 31573608
[TBL] [Abstract][Full Text] [Related]
8. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
10. Changes in pediatric DXA measures of musculoskeletal outcomes and correlation with quantitative CT following treatment of acute lymphoblastic leukemia.
Mostoufi-Moab S; Kelly A; Mitchell JA; Baker J; Zemel BS; Brodsky J; Long J; Leonard MB
Bone; 2018 Jul; 112():128-135. PubMed ID: 29679731
[TBL] [Abstract][Full Text] [Related]
11. Osteopenia in children with cerebral palsy can be treated with oral alendronate.
Paksu MS; Vurucu S; Karaoglu A; Karacalioglu AO; Polat A; Yesilyurt O; Unay B; Akin R
Childs Nerv Syst; 2012 Feb; 28(2):283-6. PubMed ID: 21928064
[TBL] [Abstract][Full Text] [Related]
12. [Clinical application of alendronate for osteoporosis/osteopenia secondary to hyperthyroidism].
Yang LJ; Shen FX; Zheng JC; Zhang HL
Zhongguo Gu Shang; 2012 Feb; 25(2):133-7. PubMed ID: 22577718
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of and Risk Factors for Low Bone Mineral Density in Children With Celiac Disease.
Webster J; Vajravelu ME; Choi C; Zemel B; Verma R
Clin Gastroenterol Hepatol; 2019 Jul; 17(8):1509-1514. PubMed ID: 31230659
[TBL] [Abstract][Full Text] [Related]
14. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.
Mondy K; Powderly WG; Claxton SA; Yarasheski KH; Royal M; Stoneman JS; Hoffmann ME; Tebas P
J Acquir Immune Defic Syndr; 2005 Apr; 38(4):426-31. PubMed ID: 15764959
[TBL] [Abstract][Full Text] [Related]
15. Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate.
Bianchi ML; Colombo C; Assael BM; Dubini A; Lombardo M; Quattrucci S; Bella S; Collura M; Messore B; Raia V; Poli F; Bini R; Albanese CV; De Rose V; Costantini D; Romano G; Pustorino E; Magazzù G; Bertasi S; Lucidi V; Traverso G; Coruzzo A; Grzejdziak AD
Lancet Respir Med; 2013 Jul; 1(5):377-85. PubMed ID: 24429202
[TBL] [Abstract][Full Text] [Related]
16. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
17. Bone mineralization defects after treatment of acute lymphoblastic leukemia ın children.
Guren Dolu M; Canbolat Ayhan A; Erguven M; Timur C; Yoruk A; Ozdemir S
Minerva Pediatr; 2015 Oct; 67(5):419-25. PubMed ID: 26377781
[TBL] [Abstract][Full Text] [Related]
18. Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy.
Tian C; Wong BL; Hornung L; Khoury JC; Rybalsky I; Shellenbarger KC; Rutter MM
Neuromuscul Disord; 2020 Jul; 30(7):599-610. PubMed ID: 32680651
[TBL] [Abstract][Full Text] [Related]
19. Alendronate for the treatment of osteopenia in anorexia nervosa: a randomized, double-blind, placebo-controlled trial.
Golden NH; Iglesias EA; Jacobson MS; Carey D; Meyer W; Schebendach J; Hertz S; Shenker IR
J Clin Endocrinol Metab; 2005 Jun; 90(6):3179-85. PubMed ID: 15784715
[TBL] [Abstract][Full Text] [Related]
20. A Validated Risk Prediction Model for Bone Fragility in Children With Acute Lymphoblastic Leukemia.
Verwaaijen EJ; Ma J; de Groot-Kruseman HA; Pieters R; van der Sluis IM; van Atteveld JE; Halton J; Fernandez CV; Hartman A; de Jonge R; Lequin MH; Te Winkel ML; Alos N; Atkinson SA; Barr R; Grant RM; Hay J; Huber AM; Ho J; Jaremko J; Koujok K; Lang B; Matzinger MA; Shenouda N; Rauch F; Rodd C; van den Heuvel-Eibrink MM; Pluijm SMF; Ward LM;
J Bone Miner Res; 2021 Dec; 36(12):2290-2299. PubMed ID: 34610647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
